[Skip to Content]
[Skip to Content Landing]
Citations 0
October 27, 2004

Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292(16):1952-1953. doi:10.1001/jama.292.16.1952-a

To the Editor: We are concerned that the recent studies on enoxaparin vs unfractionated heparin leave the duration of heparin treatment ill-defined for patients with acute coronary syndromes.

In the SYNERGY trial,1 duration of drug administration was left to the judgment of the treating physician. SYNERGY was an open-label trial, and subcutaneous enoxaparin is more convenient than intravenous unfractionated heparin, which could lead to longer treatment. Therefore, it is possible that differences between enoxaparin and unfractionated heparin may be biased by longer treatment with 1 study drug. SYNERGY did not present actual duration of treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview